Levosimendan
- Generic Name
- Levosimendan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C14H12N6O
- CAS Number
- 141505-33-1
- Unique Ingredient Identifier
- C6T4514L4E
- Background
Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.
- Indication
For short term treatment of acutely decompensated severe chronic heart failure (CHF). Also being investigated for use/treatment in heart disease.
- Associated Conditions
- Acute Decompensated Heart Failure (ADHF), Acute Decompensation of Chronic Heart Failure, Acute Heart Failure (AHF), Chronic Heart Failure (CHF), Acute post-surgical heart failure, Acute, chronic Decompensated Heart Failure, Heart failure post-myocardial infarction, Severe Decompensated Chronic Heart Failure
- Associated Therapies
- Positive cardiac inotropic effect, Intravenous inotropic therapy
A Clinical Study on Levosimendan Improvement of Prognosis of ARDS Patients by Optimizing Pulmonary Hemodynamics
- First Posted Date
- 2019-07-15
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- Shenzhen Second People's Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04020003
- Locations
- 🇨🇳
Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 227
- Registration Number
- NCT03948178
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Augusta University, Medical Centre, Augusta, Georgia, United States
🇺🇸Neurology Associates, Lincoln, Nebraska, United States
Levosimendan Versus Milrinone in Off Pump CABG Surgery
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2019-03-07
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 60
- Registration Number
- NCT03855579
- Locations
- 🇪🇬
Assiut University, Assiut, Egypt
Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic Heart Failure in Order to Prevent Rehospitalizations
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Collegium Medicum w Bydgoszczy
- Target Recruit Count
- 100
- Registration Number
- NCT03764722
- Locations
- 🇵🇱
Second Department of Cardiology, Bydgoszcz, Poland
Clinical Trial in Patients Who Have Suffered a Heart Attack and Who Have Undergone Catheterization Treated With Levosimendan
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Hospital Universitario de Canarias
- Target Recruit Count
- 184
- Registration Number
- NCT03699215
- Locations
- 🇪🇸
UICEC, La Laguna, S/C De Tenerife, Spain
Effect of Levosimendan or Placebo on Exercise in Advanced Chronic Heart Failure
- First Posted Date
- 2018-07-03
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Finn Gustafsson
- Target Recruit Count
- 42
- Registration Number
- NCT03576677
- Locations
- 🇩🇰
Department of Cardiology, The Heart Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
🇩🇰Department of Cardiology, Odense University Hospital, Odense, Denmark, Odense, Denmark
🇩🇰Department of Cardiology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark, Herlev, Denmark
Levosimendan for Cardiac Patients Undergoing Major Abdominal Cancer Surgeries
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- National Cancer Institute, Egypt
- Target Recruit Count
- 60
- Registration Number
- NCT03557255
- Locations
- 🇪🇬
Department of Anesthesia and Pain medicine.National Cancer Institute, Cairo, Egypt
Evaluate the Efficacy and Safety of Short-term Administration of SIMDAX
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Yooyoung Pharmaceutical Co., Ltd.
- Target Recruit Count
- 112
- Registration Number
- NCT03555123
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
- Conditions
- Hypertension Pulmonary SecondaryHeart Failure, Right SidedHeart Failure With Normal Ejection Fraction
- Interventions
- Drug: LevosimendanDrug: Matching Placebo
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Tenax Therapeutics, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT03541603
- Locations
- 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 496
- Registration Number
- NCT03505021
- Locations
- 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇨🇦Moncton Hospital, Southeast Regional Health Authority, Moncton, New Brunswick, Canada
🇺🇸Hospital for Special Care, New Britain, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.